Patents Assigned to Nycomed AS
-
Patent number: 8906411Abstract: A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g. tablets.Type: GrantFiled: December 7, 2006Date of Patent: December 9, 2014Assignee: Takeda Nycomed ASInventors: Poul Egon Bertelsen, Peder Mohr Olsen
-
Patent number: 8846088Abstract: A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound.Type: GrantFiled: February 2, 2006Date of Patent: September 30, 2014Assignee: Takeda Nycomed ASInventors: Poul Egon Bertelsen, Peder Mohr Olsen, Carsten Martini Nielsen, Magnus Wilhelm Tolleshaug
-
Patent number: 8846101Abstract: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties.Type: GrantFiled: December 7, 2006Date of Patent: September 30, 2014Assignee: Takeda Nycomed ASInventor: Jan Y. Piene
-
Patent number: 8808735Abstract: The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets.Type: GrantFiled: February 2, 2006Date of Patent: August 19, 2014Assignee: Takeda Nycomed ASInventors: Poul Egon Bertelsen, Peder Mohr Olsen, Carsten Martini Nielsen, Magnus Wilhelm Tolleshaug
-
Patent number: 8642081Abstract: The present invention relates to a nutriceutical and/or pharmaceutical composition for oral use containing a calcium-containing compound. The composition is in the form of tablets that are designed so that they have an acceptable taste and mouthfeel, whereby the tablets are chewable or suckable, and at the same time the tablets fulfill the requirements with respect to technical properties in order to ensure that the tablets can be dispensed by means of a dose-dispensing machine. In a preferred embodiment, the tablet comprises calcium carbonate and sorbitol with a mean particle size of 38 or 110 microns. In another embodiment, the tablets comprise calcium carbonate and Vitamin D as active ingredients.Type: GrantFiled: May 24, 2005Date of Patent: February 4, 2014Assignee: Takeda Nycomed ASInventors: Peder M. Olsen, Karin L. Christensen, Dina W. Sørensen
-
Patent number: 5616467Abstract: A method for the qualitative or quantitative determination of an analyte in a test sample wherein a labelled reagent is caused to be immobilized in bound form on a solid phase to provide an indication of the presence or quantity of the analyte in the sample is disclosed and is characterized in that the labelled reagent comprises a gold sol bound to a substance capable of specifically binding to said analyte or to a specific binding partner therefor, at least 75% by weight of the gold particles of the gold sol having a mean diameter of less than 5 nanometers.Type: GrantFiled: June 2, 1995Date of Patent: April 1, 1997Assignee: Nycomed ASInventors: Egil Olsen, .O slashed.rjan Olsvik
-
Patent number: 5583043Abstract: The invention relates to a perfusion chamber 1, a mixing device 21, and a cover slip holder 6 for use together with the perfusion chamber 1. The bottom of the cover slip holder 6 is provided with cross-located grooves 11, 12, 13-1 for installing cover slips 14, 15, 16-1, and in which the cover slips 14, 15, 16-1 are positioned in comparison to each other in such a way that the cross-sectional area of the flow channel 4 is constricted unilaterally, for simulation of thrombogenesis in human blood vessels with stenosis. The bottom of the perfusion chamber 1, in the measure chamber 7, can also have an elevation into the flow channel 4 in the measure chamber 7 which together with the recessed cover slip holder bottom produces a bilateral constriction of the cross-sectional area of the measure chamber 7. A mixing device 21 is connected to the system upstream of the perfusion chamber 1 and produces homogeneous mixing of solutions added to the blood flow.Type: GrantFiled: April 18, 1994Date of Patent: December 10, 1996Assignee: Hafslund Nycomed AsInventor: Kjell S. Sakariassen
-
Patent number: 5128121Abstract: There is provided a method of generating enhanced images of the human or non-human animal body, for example for use in medical diagnosis, which involves administering to the body a positive MRI contrast agent which is body tissue- or body duct-specific following the particular mode of administration and a negative MRI contrast agent which preferably also is body tissue- or body duct-specific. Thereafter a magnetic resonance image is generated of a part of the body containing the negative and positive contrast agents or their paramagnetic, ferromagnetic or superparamagnetic biodegradation products. Contrast media suitable for use in this new image generating method are also provided.Type: GrantFiled: October 9, 1990Date of Patent: July 7, 1992Assignee: Nycomed ASInventors: Arne Berg, Jo Klaveness
-
Patent number: 4986980Abstract: There is disclosed a diagnostic agent containing a non-radioactive paramagnetic metal species which agent comprises a physiologically tolerable, water-soluble, hydroxyl group-containing macromolecular product to which is chemically bound said metal species, said product consisting essentially of at least one polymeric or polymerized carbohydrate or polymerized sugar alcohol or derivative thereof.Type: GrantFiled: November 1, 1985Date of Patent: January 22, 1991Assignee: Nycomed ASInventor: Trond Jacobsen
-
Patent number: 4987122Abstract: Novel peptides consisting of dimeric peptide chains linked by a disulphide bridge. The dimers have a stimulatory effect on haemopoiesis, by contrast with the inhibitory effect of the monomer analogues.Type: GrantFiled: June 17, 1988Date of Patent: January 22, 1991Assignee: Nycomed ASInventor: Ole D. Laerum
-
Patent number: 4985233Abstract: A paramagnetic metal species-containing diagnostic agent is disclosed which comprises a non-radioactive paramagnetic metal species and, as a carrier therefor, a physiologically tolerable, water-insoluble, hydroxyl group-containing, particulate macromolecular product consisting essentially of at least one polymeric or polymerized carbohydrate or polymerized sugar alcohol or derivative thereof.Type: GrantFiled: November 1, 1985Date of Patent: January 15, 1991Assignee: Nycomed /ASInventors: Jo Klaveness, Trond Jacobsen, Bernt J. Lindberg
-
Patent number: 4863715Abstract: Ferromagnetic particles, conveniently embedded in or coated by a biotolerable polymer and held in dispersion in a physiologically acceptable dispersion medium, may be used as contrast agents in nmr imaging for the production of images suitable for use in diagnosis. Unlike paramagnetic nmr contrast agents, ferromagnetic nmr contrast agents give particularly good contrast in the T.sub.2 dependent images.Type: GrantFiled: October 31, 1985Date of Patent: September 5, 1989Assignee: Nycomed ASInventors: Trond Jacobsen, Jo Klaveness
-
Patent number: 4832940Abstract: The present invention provides targeting polypeptides for use in targeting and identifying activated T-lymphocytes in the human or animal body, the targeting polypeptides being capable of binding specifically to the interleukin-2 receptors of activated T-lymphocytes or to molecules associated with the receptors and carrying one or more physiologically compatible imaging agents. Such targeting polypeptides can be used for, example, in the location of tumours and abscesses and other inflammatory conditions and in the monitoring of tissue transplants for possible rejection.Type: GrantFiled: October 21, 1986Date of Patent: May 23, 1989Assignee: Nycomed ASInventor: Thorfinn Ege
-
Patent number: 4760173Abstract: There are provided NMR contrast agents comprising water-soluble paramagnetic metal chelates, preferably of Cr(III), Fe(III) or Gd(III), wherein the chelating entity is an anilide group containing organic moiety, preferably a compound of formula I ##STR1## wherein R.sup.1 to R.sup.5 may represent hydrogen or halogen atoms, optionally halogenated alkyl or alkoxy groups or carboxyl groups. The agents are especially suitable for use in NMR imaging of the hepatobiliary system.Type: GrantFiled: September 29, 1987Date of Patent: July 26, 1988Assignee: Nycomed ASInventor: Jo Klaveness
-
Patent number: 4714607Abstract: There are provided NMR contrast agents comprising water-soluble paramagnetic metal chelates, preferably of Cr(III), Fe(III) or Gd(III), wherein the chelating entity is an anilide group containing organic moiety, preferably a compound of formula I ##STR1## wherein R.sup.1 to R.sup.5 may represent hydrogen or halogen atoms, optionally halogenated alkyl or alkoxy groups or carboxyl groups. The agents are especially suitable for use in NMR imaging of the hepatobiliary system.Type: GrantFiled: May 30, 1985Date of Patent: December 22, 1987Assignee: Nycomed ASInventor: Jo Klaveness
-
Patent number: D703551Type: GrantFiled: May 22, 2013Date of Patent: April 29, 2014Assignee: Takeda Nycomed ASInventors: Siegfried Kirchmayr, Meinolf Vogt